San Diego-dependent Viking Therapeutics marked alone as a significant competitor while in the weight loss drug current market in February soon after revealing promising details from the mid-phase trial of experimental drug VK2735, which proposed it rivaled—and outperformed—Novo and Lilly drugs when offered like a weekly injection As well as in